10-09-2018 01:09 PM CET - Advertising, Media Consulting, Marketing Research
Print

Infertility Testing Market to 2025- Procter & Gamble, Babystart Ltd, Biozhena Corporation, Quidel Corporation, Alere Inc., SPD Swiss Precision Diagnostics GmBH, Proctor & Gamble, SCSA Diagnostics Inc

Press release from: Data Bridge Market Research
Global Infertility Testing Market
Global Infertility Testing Market
Global Infertility Testing Market report delivers a detailed study with present and upcoming Opportunities to clarify the future investment in the market. Global Infertility Testing industry 2018-2025 report shares information regarding key drivers, challenges, and Opportunities with its impact by regions. This report is a valuable source of guidance for companies and individuals offering Industry Chain Structure, Business Strategies and Proposals for New Project Investments. The report also studies the various inhibitors as well as motivators of the Global Infertility Testing Market Products market in both quantitative and qualitative manners in order to provide accurate information to the readers.

Get Free PDF Sample of Report at databridgemarketresearch.com/request-a-sample/?dbmr=globa...

In October 2017, P&G unveiled its new innovation in ovulation testing that pairs the accuracy of the Clearblue Ovulation Test, now with the app. The Clearblue Connected app will remind users when to test, display a user’s daily test results and let the user record details also.

GROWTH IN THE COLD CHAIN MARKET

Cold chain includes a series of refrigerated products, need of storage, distribution activities, logistics and other related equipment. Cold chain equipment is used in pharmaceutical sector, transportation, food sector, bio pharma, chemical sector and many more. For instance, pharmaceutical sector requires cold chain equipment for storage of vaccines, testing reagent, whole blood and refrigerated drugs. Logistic sector include transportation of horticulture, floriculture during distribution and supply. Food sector include processed foods, dairy and poultry consumption, instant and canned items. According to National Centre for Cold Chain Development (NCCD), in 2014, under Ministry of Agriculture & Farmers Welfare, support for cold chain was rationalized to revise the components and the cost norms along with a reduction of 5% in the subsidy rates.

Major Players: Global Infertility Testing Market

The Merck KGaA is going to dominate the global infertility market followed by

• Procter & Gamble,
• bioMérieux
• Babystart Ltd,
• Biozhena Corporation,
• Quidel Corporation,
• Alere Inc.,
• Biomérieux SA,
• SPD Swiss Precision Diagnostics GmBH,
• Proctor & Gamble,
• SCSA Diagnostics Inc., among others.

For More Inquiry Contact us at databridgemarketresearch.com/inquire-before-buying/?dbmr=...

Global Infertility Testing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The Merck KGaA dominated the infertility testing market accounting for a highest market share in 2016, followed by Procter & Gamble and bioMérieux SA. Other players in this market include Babystart Ltd, Biozhena Corporation, Quidel Corporation, Alere Inc., SPD Swiss Precision Diagnostics GmBH, Proctor & Gamble, SCSA Diagnostics, Inc., among others.

Market Segmentation:

On the basis of Distribution Channel, the global infertility testing market is classified into:-

• Hospitals Pharmacies,
• Online Pharmacies And
• Pharmacies & Drug Stores.

On the basis of End User, the global infertility testing market is classified into:-

• Fertility Centers,
• Hospitals And Clinics,
Research Institutes And
• Cryobanks.

TABLE OF CONTENTS GLOBAL INFERTILITY TESTING MARKET
1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL INFERTILITY TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. SIGNIFICANT DECLINE IN FERTILITY RATES
3.1.2. RISING PUBLIC AWARENESS AMONG THE FEMALE POPULATION
3.1.3. INCREASING NUMBER OF GYNAECOLOGICAL DISORDERS
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIVE TESTING PRODUCTS

3.2. RESTRAINTS

3.2.1. HIGH COST OF OVULATION TESTING
3.2.2. ACCURACY ISSUES WITH TESTING KITS

3.3. OPPORTUNITIES

3.3.1. REDUCTION IN THE COST OF INFERTILITY TREATMENT
3.3.2. EMERGENCE OF COMBINATION TESTING KITS

3.4. CHALLENGES

3.4.1. STRINGENT REGULATORY SCENARIO
3.4.2. INFERTILITY CONSIDERED AS SOCIAL TABOO

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL INFERTILITY TESTING MARKET, BY TYPE

6.1. OVERVIEW

6.2. FEMALE INFERTILITY TESTING

6.2.1. OVULATION TESTING
6.2.2. HYSTEROSALPINGOGRAPHY
6.2.3. LAPAROSCOPY
6.2.4. TRANSVAGINAL ULTRASOUND
6.2.5. OVARIAN RESERVE TESTING
6.2.6. HORMONE TESTING
6.2.7. OTHERS

6.3. MALE INFERTILITY TESTING

6.3.1. DNA FRAGMENTATION
6.3.2. OXIDATIVE STRESS ANALYSIS
6.3.3. SPERM PENETRATION ASSAY
6.3.4. COMPUTER AIDED SEMEN ANALYSIS
6.3.5. SPERM AGGLUTINATION ASSAY
6.3.6. MICROSCOPIC EXAMINATION
6.3.7. OTHERS

7. GLOBAL INFERTILITY TESTING MARKET, BY TEST KITS

7.1. OVERVIEW
7.2. FOLLICULAR STIMULATING HORMONE (FSH) URINE TEST KITS
7.3. LUTEINIZING HORMONE (LH) URINE TEST KITS
7.4. HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE BLOOD TEST KITS 67
7.5. OTHER TEST KITS

8. GLOBAL INFERTILITY TESTING MARKET, BY PRESCRIPTION MODE

8.1. OVERVIEW
8.2. PRESCRIPTION BASED
8.3. OVER THE COUNTER (OTC) BASED

9. GLOBAL INFERTILITY TESTING MARKET, BY DISTRIBUTION CHANNEL

9.1. OVERVIEW
9.2. HOSPITALS PHARMACIES
9.3. ONLINE PHARMACIES
9.4. PHARMACIES & DRUG STORES

10. GLOBAL INFERTILITY TESTING MARKET, BY END USERS

10.1. OVERVIEW
10.2. FERTILITY CENTERS
10.3. HOSPITALS AND CLINICS
10.4. RESEARCH INSTITUTES
10.5. CRYOBANKS

11. GLOBAL INFERTILITY TESTING MARKET, BY GEOGRAPHY

11.1. OVERVIEW

11.2. NORTH AMERICA

11.2.1. U.S.
11.2.2. CANADA
11.2.3. MEXICO

11.3. EUROPE

11.3.1. GERMANY
11.3.2. FRANCE
11.3.3. U.K.
11.3.4. ITALY
11.3.5. SPAIN
11.3.6. RUSSIA
11.3.7. TURKEY
11.3.8. BELGIUM
11.3.9. NETHERLANDS
11.3.10. SWITZERLAND
11.3.11. REST OF EUROPE

11.4. ASIA-PACIFIC

11.4.1. JAPAN
11.4.2. CHINA
11.4.3. INDIA
11.4.4. SOUTH KOREA
11.4.5. AUSTRALIA
11.4.6. SINGAPORE
11.4.7. THAILAND
11.4.8. MALAYSIA
11.4.9. INDONESIA
11.4.10. PHILIPPINES
11.4.11. REST OF ASIA PACIFIC

11.5. SOUTH AMERICA

11.5.1. BRAZIL
11.5.2. REST OF SOUTH AMERICA

11.6. MIDDLE EAST AND AFRICA

11.6.1. SOUTH AFRICA
11.6.2. REST OF MIDDLE EAST & AFRICA

12. GLOBAL INFERTILITY TESTING MARKET, COMPANY LANDSCAPE

12.1. COMPANY SHARE ANALYSIS: GLOBAL
12.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3. COMPANY SHARE ANALYSIS: EUROPE
12.4. COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13. COMPANY PROFILES

13.1. BABYSTART LTD

13.1.1. COMPANY OVERVIEW
13.1.2. BABYSTART LTD: COMPANY SNAPSHOT
13.1.3. PRODUCT PORTFOLIO
13.1.4. RECENT DEVELOPMENTS

13.2. BIOZHENA CORPORATION

13.2.1. COMPANY OVERVIEW
13.2.2. BIOZHENA CORPORATION:COMPANY SNAPSHOT
13.2.3. PRODUCT PORTFOLIO
13.2.4. RECENT DEVELOPMENTS

13.3. QUIDEL CORPORATION

13.3.1. COMPANY OVERVIEW
13.3.2. QUIDEL CORPORATION: REVENUE ANALYSIS
13.3.3. PRODUCT PORTFOLIO
13.3.4. RECENT DEVELOPMENTS

13.4. ALERE INC.

13.4.1. COMPANY OVERVIEW
13.4.2. ALERE INC.: REVENUE ANALYSIS
13.4.3. PRODUCT PORTFOLIO
13.4.4. RECENT DEVELOPMENTS

13.5. BIOMÉRIEUX

13.5.1. COMPANY OVERVIEW
13.5.2. BIOMÉRIEUX: REVENUE ANALYSIS
13.5.3. PRODUCT PORTFOLIO
13.5.4. RECENT DEVELOPMENTS

13.6. SPD SWISS PRECISION DIAGNOSTICS GMBH

13.6.1. COMPANY OVERVIEW
13.6.2. SPD SWISS PRECISION DIAGNOSTICS GMBH: COMPANY SNAPSHOT
13.6.3. PRODUCT PORTFOLIO
13.6.4. RECENT DEVELOPMENTS

13.7. PROCTER & GAMBLE

13.7.1. COMPANY OVERVIEW
13.7.2. PROCTER & GAMBLE: REVENUE ANALYSIS
13.7.3. PRODUCT PORTFOLIO
13.7.4. RECENT DEVELOPMENTS

13.8. SCSA DIAGNOSTICS, INC.

13.8.1. COMPANY OVERVIEW
13.8.2. SCSA DIAGNOSTICS, INC: COMPANY SNAPSHOT
13.8.3. PRODUCT PORTFOLIO
13.8.4. RECENT DEVELOPMENTS

13.9. ANDROLOGY SOLUTIONS

13.9.1. COMPANY OVERVIEW
13.9.2. ANDROLOGY SOLUTIONS: COMPANY SNAPSHOT
13.9.3. PRODUCT PORTFOLIO
13.9.4. RECENT DEVELOPMENTS

13.10. ATLAS MEDICAL UK

13.10.1. COMPANY OVERVIEW
13.10.2. ATLAS MEDICAL UK: COMPANY SNAPSHOT
13.10.3. PRODUCT PORTFOLIO
13.10.4. RECENT DEVELOPMENTS

13.11. HALOTECH DNA

13.11.1. COMPANY OVERVIEW
13.11.2. HALOTECH DNA: COMPANY SNAPSHOT
13.11.3. PRODUCT PORTFOLIO
13.11.4. RECENT DEVELOPMENTS

13.12. SA SCIENTIFIC

13.12.1. COMPANY OVERVIEW
13.12.2. SA SCIENTIFIC: COMPANY SNAPSHOT
13.12.3. PRODUCT PORTFOLIO
13.12.4. RECENT DEVELOPMENTS

13.13. GEM MEDIC TECHNOLOGY CO.,LTD

13.13.1. COMPANY OVERVIEW
13.13.2. GEM MEDIC TECHNOLOGY CO., LTD: COMPANY SNAPSHOT
13.13.3. PRODUCT PORTFOLIO
13.13.4. RECENT DEVELOPMENTS

13.14. MERCK KGAA

13.14.1. COMPANY OVERVIEW
13.14.2. MERCK KGAA: REVENUE ANALYSIS
13.14.3. PRODUCT PORTFOLIO
13.14.4. RECENT DEVELOPMENTS

14. RELATED REPORTS

Customization with Discount Available on This Report at databridgemarketresearch.com/request-a-sample/?dbmr=globa...

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1290587 • Views: 292
More releasesMore releases

You can edit or delete your press release here: